Author:
Esposito Roberta,Polidori Taisia,Meise Dominik F.,Pulido-Quetglas Carlos,Chouvardas Panagiotis,Forster Stefan,Schaerer Paulina,Kobel Andrea,Schlatter Juliette,Roemmele Michaela,Westemeier Emily S.,Zhu Lina,Lanzós Andrés,Guillen-Ramirez Hugo A.,Basile Giulia,Carrozzo Irene,Vancura Adrienne,Ullrich Sebastian,Andrades Alvaro,Harvey Dylan,Medina Pedro P.,Ma Patrick C.,Haefliger Simon,Wang Xin,Martinez Ivan,Ochsenbein Adrian,Riether Carsten,Johnson Rory
Abstract
AbstractLong noncoding RNAs (lncRNAs) are widely dysregulated in cancer, yet their functional roles in cellular disease hallmarks remain unclear. Here we employ pooled CRISPR deletion to perturb all 831 lncRNAs in KRAS-mutant non-small cell lung cancer (NSCLC), and measure their contribution to proliferation, chemoresistance and migration across two cell backgrounds. Integrative analysis of this data outperforms conventional “dropout” screens in identifying cancer genes, while prioritising disease-relevant lncRNAs with pleiotropic and background-independent roles. Altogether 60 high-confidence oncogenic lncRNAs are active in NSCLC, the majority identified here for the first time, and which tend to be amplified and overexpressed in tumours. A follow-up antisense oligonucleotide (ASO) screen shortlisted two candidates, Cancer Hallmarks in Lung LncRNA (CHiLL 1&2), whose knockdown consistently suppressed cancer hallmarks in a variety of 2D and 3D tumour models. Molecular phenotyping reveals that CHiLL 1&2 control cellular-level phenotypes via distinct transcriptional networks converging on common oncogenic pathways. In summary, this work reveals a multi-dimensional functional lncRNA landscape underlying NSCLC that contains potential therapeutic vulnerabilities.
Publisher
Cold Spring Harbor Laboratory
Reference120 articles.
1. Gridelli C , Rossi A , Carbone DP , Guarize J , Karachaliou N , Mok T , et al. Non-small-cell lung cancer [Internet]. Nat. Rev. Dis. Prim. Nature Publishing Group; 2015 [cited 2021 Jun 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/27188576/
2. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC);Cell Reports Med. Cell Press,2021
3. Rotow J , Bivona TG. Understanding and targeting resistance mechanisms in NSCLC [Internet]. Nat. Rev. Cancer. Nature Publishing Group; 2017 [cited 2021 Apr 27]. page 637–58. Available from: https://pubmed.ncbi.nlm.nih.gov/29068003/
4. Hong DS , Fakih MG , Strickler JH , Desai J , Durm GA , Shapiro GI , et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. https://doi.org/101056/NEJMoa1917239 [Internet]. Massachusetts Medical Society; 2020 [cited 2021 Sep 8];383:1207–17. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1917239
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献